{
    "abstract": "Atezolizumab is becoming a significant therapy for non-small cell lung cancer (NSCLC), but its efficacy needs to be further improved. The aims of this study are to clarify the potency of atezolizumab-based therapy in advanced NSCLC patients with different clinical and molecular features, and to choose a better therapeutic regimen of atezolizumab to achieve more precise treatment in immunotherapy.\nRandomized clinical trials (RCTs) in the Cochrane Library, PubMed, Embase Science Direct, and Google Scholar, together with major oncology conferences that compared atezolizumab with chemotherapy-based treatment for individuals with advanced NSCLC published prior to February 2022, were searched. Studies, bias risk assessment, and data extraction were selected by two independent authors. We extracted the basic features of the included studies, together with the 95% confidence interval (CI) and hazard ratios (HRs), from all patients and subgroups. The combined treatment data were assessed using the inverse variance weighting method.\nSeven RCTs including 4,859 patients were included. Our meta-analysis findings indicated that atezolizumab substantially enhanced OS (HR 0.82; 95% CI, 0.77-0.88; \nAge group, smoking history, liver metastasis status, EGFR mutation status, race, and PD-L1 expression can be used to predict the potency of atezolizumab and provide a better treatment regimen for patients with advanced NSCLC to achieve accurate and personalized treatment.",
    "authors": [
        {
            "affiliation": "Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, China.",
            "firstname": "Wenjie",
            "initials": "W",
            "lastname": "Liu"
        },
        {
            "affiliation": "Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, China.\nDepartment of Oncology, Jining No. 1 People's Hospital, Jining, China.",
            "firstname": "Gengwei",
            "initials": "G",
            "lastname": "Huo"
        },
        {
            "affiliation": "Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, China.",
            "firstname": "Peng",
            "initials": "P",
            "lastname": "Chen"
        }
    ],
    "conclusions": null,
    "copyrights": "Copyright \u00a9 2022 Liu, Huo, and Chen.",
    "doi": "10.3389/fimmu.2022.909027\n10.3322/caac.21551\n10.1186/s13046-018-0984-z\n10.1002/j.1460-2075.1992.tb05481.x\n10.1016/j.immuni.2013.07.012\n10.1038/s41568-019-0116-x\n10.1634/theoncologist.2017-0078\n10.1016/j.ejca.2016.12.041\n10.52586/S562\n10.1186/s13045-019-0779-5\n10.1007/s40259-022-00515-z\n10.1007/978-3-319-53156-4_5\n10.1016/j.immuni.2019.12.011\n10.3390/ijms22105123\n10.1016/j.lungcan.2016.05.001\n10.1016/j.jtho.2016.06.006\n10.1038/ni.2691\n10.1038/nature14011\n10.1016/S0140-6736(16)00587-0\n10.1056/NEJMoa1917346\n10.1016/j.jtho.2019.12.107\n10.3390/cancers13030558\n10.1038/s41591-018-0134-3\n10.1016/j.jtho.2016.02.015\n10.1126/science.aaf1490\n10.1001/jamaoncol.2018.5152\n10.1001/jamaoncol.2017.4427\n10.1016/S0140-6736(16)32517-X\n10.1016/j.jtho.2018.04.039\n10.1056/NEJMoa1716948\n10.1016/S2213-2600(19)30084-0\n10.1016/j.jtho.2021.07.009\n10.1016/j.jtho.2021.09.014\n10.1016/S1470-2045(19)30167-6\n10.1016/j.jtho.2020.03.028\n10.1016/j.jtho.2020.11.025\n10.1016/j.jtho.2021.06.019\n10.1111/1759-7714.14178\n10.1155/2019/9853701\n10.1016/j.ctrv.2017.08.003\n10.1016/j.ejca.2017.05.044\n10.1053/j.seminoncol.2018.09.001\n10.1016/j.ctrv.2016.02.006\n10.1038/nri.2016.90\n10.18632/oncotarget.22242\n10.1136/esmoopen-2018-000344\n10.1016/j.eururo.2018.07.004\n10.1001/jamaoncol.2018.5904\n10.1002/cam4.2280\n10.1097/JTO.0000000000000630\n10.5858/arpa.2011-0521-OA\n10.3322/caac.21596\n10.1016/j.lungcan.2020.04.027\n10.1111/crj.12742\n10.2147/OTT.S156421\n10.1186/s12957-020-1792-4\n10.1002/cncr.31871\n10.1001/jamaoncol.2016.0639\n10.1038/nature09004\n10.1126/science.aaa1348\n10.1016/j.cell.2012.08.024\n10.1016/j.jtho.2017.04.027\n10.18632/oncotarget.10644\n10.3892/mco.2014.410\n10.1016/j.critrevonc.2020.102893\n10.21873/anticanres.12779\n10.1002/eji.200526034\n10.4049/jimmunol.172.9.5222\n10.4049/jimmunol.171.12.6339\n10.1158/1078-0432.CCR-16-1401\n10.1002/cncr.32468\n10.1016/j.jtho.2018.09.012\n10.1158/1078-0432.CCR-19-0585\n10.1200/JCO.2017.75.3384\n10.1093/annonc/mdz141\n10.21037/tlcr.2020.01.03\n10.1158/1078-0432.CCR-17-2156\n10.1016/j.jtho.2020.12.010\n10.1186/s12943-019-1062-7\n10.21037/tlcr-20-246\n10.1073/pnas.1802166115\n10.1200/JCO.2016.71.9476\n10.2217/imt-2016-0150\n10.3389/fimmu.2018.01310\n10.1200/JCO.21.01497\n10.1016/j.trecan.2015.07.008\n10.1016/j.ccell.2015.10.012\n10.4161/onci.27025\n10.1038/cdd.2013.67",
    "journal": "Frontiers in immunology",
    "keywords": [
        "atezolizumab",
        "meta-analysis",
        "non-small cell lung cancer",
        "potency",
        "predictor"
    ],
    "methods": null,
    "publication_date": "2022-07-09",
    "pubmed_id": "35799785\n30620402\n30577808\n1396582\n23890059\n30755690\n28835513\n28407528\n34879471\n31488176\n35147894\n28321814\n31940268\n34066087\n27237031\n27346415\n24048121\n25428504\n26970723\n32997907\n31870882\n33535621\n30082870\n26944305\n26940869\n30347025\n29270615\n27979383\n29777823\n29863955\n30922878\n34311108\n34626838\n31122901\n32302702\n33333328\n34265434\n34612011\n31214620\n28889085\n28689093\n30446167\n26946217\n27546235\n29245905\n29682332\n30031571\n30605213\n31165589\n26291008\n23194048\n31944278\n32417680\n29115057\n29983577\n31959178\n30548240\n27310809\n20505728\n25765070\n22980976\n28838713\n27449299\n25469298\n32065969\n30061241\n16163670\n15100260\n14662830\n27470969\n31691957\n30267840\n31085721\n29337640\n31086949\n32206553\n29074606\n33388477\n31526368\n32953491\n30297397\n28609226\n28472902\n29942309\n34985920\n26457331\n26678337\n24353914\n23787994",
    "results": "Seven RCTs including 4,859 patients were included. Our meta-analysis findings indicated that atezolizumab substantially enhanced OS (HR 0.82; 95% CI, 0.77-0.88; ",
    "title": "Efficacy of Atezolizumab for Advanced Non-Small Cell Lung Cancer Based on Clinical and Molecular Features: A Meta-Analysis.",
    "xml": "<Element 'PubmedArticle' at 0x788503e08720>"
}